Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 94.
v. lappuse
... determining the actual effective date . In instances where the effective date is beyond the cut- off date for the Code a note has been inserted to reflect the future effective date . In those instances where a regulation published in ...
... determining the actual effective date . In instances where the effective date is beyond the cut- off date for the Code a note has been inserted to reflect the future effective date . In those instances where a regulation published in ...
10. lappuse
... determination that it is acceptable for licensure , be approved as a new drug application in lieu of issuance of a bio- logical product license . [ 40 FR 31312 , July 25 , 1975 ] §310.6 Applicability of " new drug " or safety or ...
... determination that it is acceptable for licensure , be approved as a new drug application in lieu of issuance of a bio- logical product license . [ 40 FR 31312 , July 25 , 1975 ] §310.6 Applicability of " new drug " or safety or ...
11. lappuse
... determination can readily be made as to the applicability of a drug efficacy notice by an individ- ual who is knowledgeable about drugs and their indications for use . Where the relationships are more subtle and not readily recognized ...
... determination can readily be made as to the applicability of a drug efficacy notice by an individ- ual who is knowledgeable about drugs and their indications for use . Where the relationships are more subtle and not readily recognized ...
20. lappuse
... determination of whether there are or may be grounds under section 505 ( e ) of the act for suspending or with- drawing ... determining the safety and effectiveness of long - term use of such drugs , extensive animal and clini- cal tests ...
... determination of whether there are or may be grounds under section 505 ( e ) of the act for suspending or with- drawing ... determining the safety and effectiveness of long - term use of such drugs , extensive animal and clini- cal tests ...
28. lappuse
... determination of the cause of these symptoms must be at- tempted before further drug administration . Patients with ... determining the presence and nature of these cardiac toxic disturbances . Digoxin may also induce other changes ( as ...
... determination of the cause of these symptoms must be at- tempted before further drug administration . Patients with ... determining the presence and nature of these cardiac toxic disturbances . Digoxin may also induce other changes ( as ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning